PTC THERAPEUTICS INC (PTCT) Stock Analyst Ratings
USA - NASDAQ:PTCT - US69366J2006 - Common Stock
71.78 USD
-0.81 (-1.12%)
71.78 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 78% to PTCT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 69.63. This target is -2.99% below the current price.
PTCT was analyzed by 23 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about PTCT.
In the previous month the buy percentage consensus was at a similar level.
PTCT was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-05 | TD Cowen | Maintains | Hold -> Hold |
| 2025-11-05 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-11-05 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-28 | Jefferies | Maintains | Buy -> Buy |
| 2025-09-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-07-29 | UBS | Maintains | Buy -> Buy |
| 2025-07-29 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-29 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-29 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-28 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-06-17 | Truist Securities | Initiate | Buy |
| 2025-05-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-09 | B of A Securities | Upgrade | Neutral -> Buy |
| 2025-05-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-07 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-05-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-07 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-07 | Citigroup | Upgrade | Sell -> Neutral |
| 2025-04-22 | RBC Capital | Reiterate | Outperform -> Outperform |
PTC THERAPEUTICS INC / PTCT FAQ
What is the average price target for PTC THERAPEUTICS INC (PTCT) stock?
23 analysts have analysed PTCT and the average price target is 69.63 USD. This implies a price decrease of -2.99% is expected in the next year compared to the current price of 71.78.
How do analysts rate PTC THERAPEUTICS INC (PTCT)?
The consensus rating for PTC THERAPEUTICS INC (PTCT) is 78.2609 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed PTC THERAPEUTICS INC (PTCT)?
The number of analysts covering PTC THERAPEUTICS INC (PTCT) is 23.